CN101896815A - 肠疾病中的新的治疗靶标 - Google Patents

肠疾病中的新的治疗靶标 Download PDF

Info

Publication number
CN101896815A
CN101896815A CN2008801210743A CN200880121074A CN101896815A CN 101896815 A CN101896815 A CN 101896815A CN 2008801210743 A CN2008801210743 A CN 2008801210743A CN 200880121074 A CN200880121074 A CN 200880121074A CN 101896815 A CN101896815 A CN 101896815A
Authority
CN
China
Prior art keywords
pxr
gene
protein
fragment
rifax
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2008801210743A
Other languages
English (en)
Chinese (zh)
Inventor
F·J·冈萨雷斯
L·约翰逊
X·马
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Salix Pharmaceuticals Inc
US Department of Health and Human Services
Original Assignee
Salix Pharmaceuticals Inc
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salix Pharmaceuticals Inc, US Department of Health and Human Services filed Critical Salix Pharmaceuticals Inc
Publication of CN101896815A publication Critical patent/CN101896815A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN2008801210743A 2007-10-17 2008-10-16 肠疾病中的新的治疗靶标 Pending CN101896815A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99923407P 2007-10-17 2007-10-17
US60/999234 2007-10-17
PCT/US2008/080115 WO2009052255A2 (en) 2007-10-17 2008-10-16 Novel therapeutic targets in bowel disease

Publications (1)

Publication Number Publication Date
CN101896815A true CN101896815A (zh) 2010-11-24

Family

ID=40568065

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008801210743A Pending CN101896815A (zh) 2007-10-17 2008-10-16 肠疾病中的新的治疗靶标

Country Status (7)

Country Link
US (1) US20110055943A1 (https=)
EP (1) EP2201372A4 (https=)
JP (1) JP2011501672A (https=)
CN (1) CN101896815A (https=)
AU (1) AU2008312464A1 (https=)
MX (1) MX2010004333A (https=)
WO (1) WO2009052255A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108267522A (zh) * 2017-12-28 2018-07-10 北京和合医学诊断技术股份有限公司 检测血液中奥氮平药物含量的液相色谱分析方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
WO2009137672A1 (en) * 2008-05-07 2009-11-12 Salix Pharmaceuticals, Ltd. Methods of treating bowel disease by administering a bowel cleanser and an antibiotic
CN110470771B (zh) * 2019-09-05 2021-06-01 清华大学 一种评价转基因植物食用安全性的方法
CN117031004B (zh) * 2023-08-09 2024-10-01 四川省医学科学院·四川省人民医院 一种检测网膜素-1的试剂在制备预测或评估ibs患者生活质量的产品中的应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HAI-LIN FANG ET AL.: "Positive and Negative Regulation of Human Hepatic Hydroxysteroid Sulfotransferase (SULT2A1) Gene Transcription by Rifampicin: Roles of Hepatocyte Nuclear Factor 4 and Pregnane X Receptor", 《 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS》 *
XIAOCHAO MA， ET AL: "Rifaximin Is a Gut-Specific Human Pregnane X Receptor Activator", 《THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108267522A (zh) * 2017-12-28 2018-07-10 北京和合医学诊断技术股份有限公司 检测血液中奥氮平药物含量的液相色谱分析方法

Also Published As

Publication number Publication date
WO2009052255A3 (en) 2009-06-11
EP2201372A2 (en) 2010-06-30
MX2010004333A (es) 2010-11-30
EP2201372A4 (en) 2010-11-10
JP2011501672A (ja) 2011-01-13
WO2009052255A2 (en) 2009-04-23
US20110055943A1 (en) 2011-03-03
AU2008312464A1 (en) 2009-04-23

Similar Documents

Publication Publication Date Title
US6358698B1 (en) Methods of identifying inverse agonists of the serotonin 2A receptor
AU2002247939B2 (en) Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
US20050148018A1 (en) Methods of identifying inverse agonists of the serotonin 2A receptor
Kelly et al. Developmental etiology for neuroanatomical and cognitive deficits in mice overexpressing Gαs, a G-protein subunit genetically linked to schizophrenia
US12509729B2 (en) Compositions and methods for the diagnosis and treatment of lymphatic system disorders
US20120208750A1 (en) Use of protein kinase c delta (pkcd) inhibitors to treat diabetes, obesity, and hepatic steatosis
CN101896815A (zh) 肠疾病中的新的治疗靶标
CN101466410B (zh) 新型治疗和诊断产品及方法
US12533362B2 (en) Methods for treating diseases associated with ciliopathies
US20170355997A1 (en) Methods and compositions for treating or preventing pruritis
Mechanic et al. Involvement of the neurotensin receptor 1 in the behavioral effects of two neurotensin agonists, NT-2 and NT69L: lack of hypothermic, antinociceptive and antipsychotic actions in receptor knockout mice
Keller et al. What the BTBR/J mouse has taught us about diabetes and diabetic complications
CN101501188A (zh) Pas激酶调控能量内环境稳定
JP6825910B2 (ja) Ｆｌａｔｔｏｐ（Ｆｌｔｐ）はβ細胞成熟についての新規のバイオマーカーである
CN115074368A (zh) 一种耐药型类风湿性关节炎动物模型的构建及其应用
WO1998032878A1 (en) Gene based assay for agents with potential therapeutic efficacy in the treatment of obsessive compulsive disorder and disorders related thereto
Buqaileh The Role of Muscarinic Acetylcholine Receptor 3 in the Pathogenesis of Polycystic Kidney Disease
US20060200870A1 (en) Methods of treating muscular dystrophy
Meqdad Role of Ciliary Muscarinic Acetylcholine Receptor 1 in Hypertension in Polycystic Kidney Disease
HK40079819A (en) Compositions and methods for the diagnosis and treatment of lymphatic system disorders
Oliveros Novel Therapeutic Strategies for Alzheimer’s Disease: Targeting Toll-Like Receptor Signaling and a Multi-Target Approach
Smith Defining the Role of c-Jun N-terminal Kinase (JNK) Signaling in Autosomal Dominant Polycystic Kidney Disease
Schürmann Endogenous opioid peptides in drug addiction
Franke et al. Dependence of erythromycin metabolism on ABCC2 (MRP2) transport function

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20101124